Hepatitis B Vaccine (Recombinant) Market Size, Market Share, Data Analysis and Forecasts, 2023-2030 | Market Study by RationalStat
November 09, 2023 08:00 ET
|
Rationalstat LLC
Wilmington, Delaware, Nov. 09, 2023 (GLOBE NEWSWIRE) -- According to RationalStat’s most recent industry analysis, the Global Hepatitis B Vaccine (Recombinant) Market value is estimated at US$ 6.5...
HilleVax to Present at Upcoming Investor Conferences
November 01, 2023 16:48 ET
|
HilleVax, Inc.
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
October 31, 2023 08:00 ET
|
Icosavax, Inc.
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda
October 19, 2023 09:16 ET
|
Sabin Vaccine Institute
WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers...
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference
October 17, 2023 07:00 ET
|
AC Immune SA
AC Immune Announces Upcoming Presentations at the 16th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...
Study Published in Science Translational Medicine Shows Exbaq’s Experimental Vaccine Protects Against Many of the Most Dangerous Antibiotic Resistant Superbugs Causing Hospital Acquired Infections
October 05, 2023 09:00 ET
|
Exbaq LLC
Vaccine Stimulates the Body’s Macrophages, Engulfing and Killing Gram Positive/Negative Bacteria, and FungiVaccine provides protection against infections within 24hours and protection lasts for up to...
HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
September 26, 2023 16:01 ET
|
HilleVax, Inc.
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Paediatric Vaccine Market Projections: Surging at a Striking 13.1% CAGR, Anticipating US$ 184,706.7 Million Valuation by 2033 | Future Market Insights, Inc.
September 25, 2023 13:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del:, Sept. 25, 2023 (GLOBE NEWSWIRE) -- In 2023, the paediatric vaccine market is expected to be worth US$ 54,130.1 million. The market is expected to grow at a remarkable 13.1% CAGR to a...
HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
September 25, 2023 07:00 ET
|
HilleVax, Inc.
BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it...
Vaccinex, Inc. Announces Reverse Stock Split
September 22, 2023 16:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...